Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | PHGDH | O43175 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5844650 | 0.91 | MGLL (0.47) | MGLLPHGDHTDP1CYP1A2ALDH1A1 | |
| SCHEMBL4421353 | 0.85 | — | — | |
| SCHEMBL5997632 | 0.85 | CA12 (0.44) | MGLLPHGDHCYP1A2ALDH1A1NPSR1 | |
| Tert-Butyl Formate SCHEMBL27555938 | 0.78 | TDP1 (0.43) | MGLLPHGDHTDP1CYP1A2ALDH1A1 | |
| SCHEMBL13895251 | 0.74 | MGLL (0.56) | MGLLPHGDHTDP1CYP1A2ALDH1A1 | |
| SCHEMBL12998880 | 0.74 | CYP1A2 (0.48) | MGLLPHGDHTDP1CYP1A2ALDH1A1 | |
| SCHEMBL12781851 | 0.74 | — | — | |
| SCHEMBL10917792 | 0.74 | MGLL (0.56) | MGLLPHGDHTDP1CYP1A2ALDH1A1 | |
| SCHEMBL10917797 | 0.74 | MGLL (0.56) | MGLLPHGDHTDP1CYP1A2ALDH1A1 | |
| SCHEMBL2693943 | 0.74 | MGLL (0.56) | MGLLPHGDHTDP1CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510413-A | DCLK1 kinase inhibitor and preparation method and application thereof | 杭州医学院 | 2024-02-06 | — | — | CN | claimed |
| US-20170166538-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-06-15 | — | — | US | claimed |
| US-12378209-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2025-08-05 | — | — | US | disclosed |
| WO-2025151517-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MISSFOLDING OF ALPHA-SYNUCLEIN PROTEIN | WAVEBREAK THERAPEUTICS LIMITED (US) | 2025-07-17 | — | — | WO | disclosed |
| CN-117510413-A | DCLK1 kinase inhibitor and preparation method and application thereof | 杭州医学院 | 2024-02-06 | — | — | CN | disclosed |
| US-20220332690-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2022-10-20 | — | — | US | disclosed |
| US-11312693-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2022-04-26 | — | — | US | disclosed |
| US-11312693-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2022-04-26 | — | — | US | disclosed |
| WO-2022062357-A1 | MEDICINE FOR TREATING OR PREVENTING DISEASES RELATED TO ACTIVITY OF LRRK2 KINASE OR ABNORMAL LRRK2 MUTANT KINASE | 广州智睿医药科技有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-20210017140-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017140-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2021-01-21 | — | — | US | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
| EP-1062212-A1 | HETEROCYCLYL ANTHRACYCLINONE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999046253-A1 | HETEROCYCLYL ANTHRACYCLINONE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-09-16 | — | — | WO | disclosed |
| EP-0824535-A1 | ANTIBACTERIAL CEPHALOSPORINS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035692-A1 | ANTIBACTERIAL CEPHALOSPORINS | BIOCHEMIE GESELLSCHAFT MBH (AT) | 1996-11-14 | — | — | WO | disclosed |
| US-4892879-A | 1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and tetrahydro-pyridines useful as anxioltic, psychogeriatric, antisepressant and antischiziphrenic agents | SANDOZ PHARM. CORP. (US) | 1990-01-09 | — | — | US | disclosed |
| US-4737500-A | 1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and -tetrahydropyridines useful as anxiolytic, psychogeriatric, antidepressant and antischizophrenic agents | SANDOZ PHARM. CORP. (US) | 1988-04-12 | — | — | US | disclosed |
| US-4064244-A | ANOREXIGENIC AGENTS, ANTIMIGRAINE AGENTS | SANDOZ LTD. (CH) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312693-B2 | Protease inhibitors | CTSK, CTSF, CTSS | MGLL 2431/4885PHGDH 4499/4885TDP1 3596/4885 |
| US-12378209-B2 | Protease inhibitors | MMP26, CTSK, TMPRSS6 | MGLL 2372/4885PHGDH 4423/4885TDP1 3526/4885 |
| US-20210017140-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | MGLL 2431/4885PHGDH 4499/4885TDP1 3596/4885 |
| US-20170166538-A1 | PROTEASE INHIBITORS | MMP8, CTSK, CTSS | MGLL 2162/4885PHGDH 4484/4885TDP1 3392/4885 |
| US-20220332690-A1 | PROTEASE INHIBITORS | MMP26, CTSK, TMPRSS6 | MGLL 2372/4885PHGDH 4423/4885TDP1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.